OptimizeRx Corp. (NASDAQ:OPRX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of OptimizeRx Corp. (NASDAQ:OPRX) have been given an average recommendation of “Moderate Buy” by the twelve ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $11.8125.

A number of research firms recently weighed in on OPRX. Zacks Research raised OptimizeRx from a “hold” rating to a “strong-buy” rating in a research report on Friday, September 5th. Wall Street Zen upgraded OptimizeRx from a “hold” rating to a “buy” rating in a report on Thursday, May 22nd. Citigroup reaffirmed an “outperform” rating on shares of OptimizeRx in a research report on Tuesday, May 13th. B. Riley restated a “buy” rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Finally, Stifel Nicolaus lifted their target price on shares of OptimizeRx from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, August 8th.

OptimizeRx Price Performance

OPRX stock opened at $17.79 on Wednesday. The firm has a 50 day moving average price of $15.09 and a 200-day moving average price of $11.61. OptimizeRx has a 52-week low of $3.78 and a 52-week high of $19.25. The firm has a market capitalization of $330.27 million, a price-to-earnings ratio of -32.94 and a beta of 1.20. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.57 and a current ratio of 2.57.

Hedge Funds Weigh In On OptimizeRx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC increased its holdings in shares of OptimizeRx by 600.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock worth $29,000 after purchasing an additional 1,818 shares in the last quarter. GAMMA Investing LLC bought a new stake in OptimizeRx in the 1st quarter worth about $33,000. Quantbot Technologies LP purchased a new position in OptimizeRx in the 2nd quarter worth about $44,000. Wells Fargo & Company MN raised its position in OptimizeRx by 33.3% in the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock worth $54,000 after buying an additional 2,797 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after acquiring an additional 2,215 shares during the period. 76.47% of the stock is owned by institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.